ArticleJournal of neurology2012
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study.
Article in Journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.Journal of neurology · 2013Trial
- Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.Therapeutic advances in neurological disorders · 2025Review
- PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.Journal of neurology · 2022Article
- Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression.Advances in therapy · 2021Article
- Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile.Arquivos de neuro-psiquiatria · 2021Observational
- Infusion-related events during natalizumab: No need for post-infusion monitoring.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?Clinical neuroradiology · 2020Article
- Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.PloS one · 2020Article
- Natalizumab: Perspectives from the Bench to Bedside.Cold Spring Harbor perspectives in medicine · 2018Review
- Extended interval dosing of natalizumab: a two-center, 7-year experience.Therapeutic advances in neurological disorders · 2014Article
- Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.Neurology · 2014Article
- Best practice in the use of natalizumab in multiple sclerosis.Therapeutic advances in neurological disorders · 2013Article
- Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natalizumab has been shown to be effective in pivotal clinical trials in multiple sclerosis; however, the patients in whom treatment is indicated in clinical practice have a different clinical profile from those included in the clinical trials. The aim of this study is therefore to collect data on natalizumab use in everyday clinical practice in Spain. The 86 participating centers throughout Spain submitted data on disease characteristics at baseline and after treatment. Valid data were available for 1,364 patients (69.3% women, 86.9% with relapsing–remitting disease).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.